Zanubrutinib Approved for Mantle Cell Lymphoma

The FDA has approved zanubrutinib (Brukinsa®, BeiGene) for patients with relapsed/refractory mantle cell lymphoma (MCL) who have received at least one previous therapy. The approval was based on two clinical trials. BGB-3111-206, a single-arm phase 2 trial, enrolled 86 patients with MCL whose disease progressed following at least one prior therapy. Patients received 160 mg of zanubrutinib orally twice daily until unacceptable toxicity or disease progression. The study's primary end point was ove...
Continue reading

Acalabrutinib, Alone or in Combination, Improves Progression-Free Survival in CLL

​ In previously untreated chronic lymphocytic leukemia (CLL), acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech), according to interim results of the phase 3 ELEVATE-TN trial to be presented at the American Society of Hematology (ASH) Annual Meeting. Acalabrutinib, a highly selective, covalent irreversible Bruton tyrosine kinase inhibitor, is currently FDA approved for the treatment of relapsed...
Continue reading

Myeloma: Bortezomib Overcomes Renal Impairment or del17p

​ Twelve-year follow-up results of the HOVON-65/GMMG-HD4 study reveal that among transplant-eligible patients with newly diagnosed multiple myeloma, those with renal impairment or chromosome deletion (del) 17p experience the most survival benefit from bortezomib-based induction and maintenance therapy. This prospective, open-label phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the German Multicenter Myeloma Group (GMMG) enrolled 827 eligible patients aged 18 to ...
Continue reading

Treatment Challenges and Advances in Hodgkin Lymphoma: Craig Moskowitz, MD, and Kami Maddocks, MD

In this exclusive with i3 Health, Craig H. Moskowitz, MD, Professor of Medicine at the University of Miami and Physician-in-Chief at the Sylvester Comprehensive Cancer Center, and Kami Maddocks, MD, Associate Professor of Clinical Internal Medicine and Lymphoma Program Director at The James Cancer Hospital at The Ohio State University, share their perspectives on the management of relapsed/refractory classical Hodgkin lymphoma (HL) and the advances brought to the treatment of this disease by dev...
Continue reading

Managing Ibrutinib-Related Hypertension in B-Cell Malignancies: Daniel Addison, MD

​ Ibrutinib is an effective treatment for several B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it can cause cardiotoxicity. Under the direction of Daniel Addison, MD, a team of researchers recently found that hypertension caused or worsened by treatment with ibrutinib results in a greater than two-fold increased risk of major adverse cardiovascular events . In this interview with i3 Health, Dr. Addison discusses wh...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.